Molecular pathogenesis of oligodendroglial tumors

被引:79
作者
Jeuken, JWM
von Deimling, A
Wesseling, P
机构
[1] Univ Med Ctr Nijmegen, Dept Pathol 437, NL-6500 HB Nijmegen, Netherlands
[2] Charite, Dept Neuropathol, Berlin, Germany
关键词
loss of heterozygosity; molecular genetics; oligoastrocytoma; oligodendroglioma; tumor suppressor gene;
D O I
10.1007/s11060-004-2748-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Based on their histopathological appearances, most diffusely infiltrative gliomas can be classified either as astrocytic tumors (As), pure oligodendroglial tumors (Os) or mixed oligoastrocytic tumors (OAs). The latter two may be grouped together as oligodendroglial tumors (OTs). The distinction between As and OTs is important because of the more favorable clinical behavior of OTs. Unfortunately, the histopathological delineation of OAs, Os and As can be difficult because of vague and subjective histopathological criteria. Over the last decade, the knowledge on the molecular genetic background of OTs has drastically increased. This review provides an overview of molecular genetic aberrations in OTs and discusses the pathobiological and clinical significance of these aberrations. In contrast to As, OTs frequently show frequent loss of heterozygosity on chromosome arms 1p and 19q. Since these aberrations are significantly correlated with clinically relevant parameters, such as prognosis and chemosensitivity, and given the difficulties in histopathological typing and grading of glial tumors, genetic testing should be included in routine glioma diagnostics. It is to be expected that the identification of the relevant tumor suppressor genes located on 1p and 19q will lead to more refined genetic tests for OTs. Furthermore, as microarray technology is rapidly increasing, it is likely that clinically relevant markers for OTs will be identified on other chromosomes and need to be included into routine glioma diagnostics as well.
引用
收藏
页码:161 / 181
页数:21
相关论文
共 132 条
[1]   Mutation analysis of the p73 gene in nonastrocytic brain tumours [J].
Alonso, ME ;
Bello, MJ ;
Gonzalez-Gomez, P ;
Lomas, J ;
Arjona, D ;
de Campos, JM ;
Kusak, ME ;
Sarasa, JL ;
Isla, A ;
Rey, JA .
BRITISH JOURNAL OF CANCER, 2001, 85 (02) :204-208
[2]  
ARSLANTAS A, 2003, NEUROSURG REV
[3]   AN INTEGRATED METRIC PHYSICAL MAP OF HUMAN-CHROMOSOME-19 [J].
ASHWORTH, LK ;
BATZER, MA ;
BRANDRIFF, B ;
BRANSCOMB, E ;
DEJONG, P ;
GARCIA, E ;
GARNES, JA ;
GORDON, LA ;
LAMERDIN, JE ;
LENNON, G ;
MOHRENWEISER, H ;
OLSEN, AS ;
SLEZAK, T ;
CARRANO, AV .
NATURE GENETICS, 1995, 11 (04) :422-427
[4]   Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas [J].
Bauman, GS ;
Ino, Y ;
Ueki, K ;
Zlatescu, MC ;
Fisher, BJ ;
Macdonald, DR ;
Stitt, L ;
Louis, DN ;
Cairncross, JG .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (03) :825-830
[5]   hRAD54 gene and 1p high-resolution deletion-mapping analyses in oligodendrogliomas [J].
Bello, MJ ;
de Campos, JM ;
Vaquero, J ;
Ruiz-Barnés, P ;
Kusak, ME ;
Sarasa, JL ;
Rey, JA .
CANCER GENETICS AND CYTOGENETICS, 2000, 116 (02) :142-147
[6]  
BELLO MJ, 1995, INT J CANCER, V64, P207
[7]   MOLECULAR ANALYSIS OF CHROMOSOME-1 ABNORMALITIES IN HUMAN GLIOMAS REVEALS FREQUENT LOSS OF 1P IN OLIGODENDROGLIAL TUMORS [J].
BELLO, MJ ;
VAQUERO, J ;
DECAMPOS, JM ;
KUSAK, ME ;
SARASA, JL ;
SAEZCASTRESANA, J ;
PESTANA, A ;
REY, JA .
INTERNATIONAL JOURNAL OF CANCER, 1994, 57 (02) :172-175
[8]   Influence of unrecognized molecular heterogeneity on randomized clinical trials [J].
Betensky, RA ;
Louis, DN ;
Cairncross, JG .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (10) :2495-2499
[9]   Amplification and overexpression of MDM2 in primary (de novo) glioblastomas [J].
Biernat, W ;
Kleihues, P ;
Yonekawa, Y ;
Ohgaki, H .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1997, 56 (02) :180-185
[10]  
Bigner S H, 1999, Neuro Oncol, V1, P52, DOI 10.1093/neuonc/1.1.52